Rory Shallis, MD

2026

• Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax A Multicenter Cohort Study

  Filimon S, Ghamari A, Vakilpour A, Patel R, Achar R, Akhter N, Shallis R, DeCara J, Altman J, Smith A, Matthews A, Lai C, Brunner A, Farina K, Gilman H, Neilan T, Upadhyay D, Chittams J, Anazco F, Patel A, Tremblay D, Scherrer-Crosbie M. Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax A Multicenter Cohort Study. JACC Advances 2026, 5: 102821. PMID: 42312783, PMCID: PMC13308248, DOI: 10.1016/j.jacadv.2026.102821.

  Peer-Reviewed Original Research

  Altmetric

• NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

  Pollyea D, Altman J, Assi R, Bachiashvili K, Bhatt V, Fathi A, Fedorov K, Foran J, Gojo I, Goldberg A, Hall A, Jonas B, Levine M, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Patel A, Percival M, Perl A, Pettit K, Rao D, Ravandi F, Schwabkey Z, Shallis R, Stahl M, Stone R, Thota S, Uy G, Walker A, Wang E, Awotiwon A, Roth S, Stehman K. NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. Journal Of The National Comprehensive Cancer Network 2026, 24: 222-229. PMID: 42297017, DOI: 10.6004/jnccn.2026.0028.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  Altmetric

  MeSH Keywords

• Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia

  Ito S, Potnis K, Ng D, Patel K, Sra M, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia. Blood Red Cells & Iron 2026, 2: 100076. PMID: 42077391, PMCID: PMC13134686, DOI: 10.1016/j.brci.2026.100076.

  Peer-Reviewed Original Research

  This study investigates how trainee-led teams developed updated consensus guidelines for managing peritoneal surface malignancies, demonstrating effective collaboration models for complex medical evidence synthesis.

  Full Summary

• Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

  Mohty R, Narra R, Mims A, Hunter C, Shallis R, Kota V, Jamy O, Coltoff A, Othman T, Jonas B, Patel A, DuVall A, Foucar C, Abdelsamia M, Palmisiano N, Patel S, Curran E, Omer Z, Advani A, Atallah E, Litzow M, Badar T. Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia & Lymphoma 2026, 67: 1587-1594. PMID: 41954351, DOI: 10.1080/10428194.2026.2650679.

  Peer-Reviewed Original Research

  This study investigates predictors of complete molecular response (CMR) and shows that early CMR improves relapse-free survival in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.

  Full Summary

• Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

  Berton G, Bewersdorf J, Gilhodes J, Iat A, Soua A, DeAngelo D, Boussi L, Shallis R, Žučenka A, Bystrom R, Ling K, Aguirre L, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Mendez L, Podoltsev N, Tauveron-Jalenques U, Lanino L, Stein E, Zeidan A, Forcade E, Cluzeau T, Dumas P, Heiblig M, Devillier R, Shimony S, Goldberg A, Stahl M, Garciaz S. Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia. Haematologica 2026 PMID: 41924924, DOI: 10.3324/haematol.2025.300202.

  Peer-Reviewed Original Research

  Altmetric

• CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

  Komrokji R, Komrokji Z, Al Ali N, Xie Z, Chan O, Kuykendall A, Walker A, Yun S, Reynolds S, Shallis R, Lancet J, Sallman D, Padron E. CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML? Blood Neoplasia 2026, 3: 100224. PMID: 42232990, PMCID: PMC13223902, DOI: 10.1016/j.bneo.2026.100224.

  Peer-Reviewed Original Research

  Altmetric

• Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia

  Iqbal U, Shallis R. Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia. Frontiers In Cell And Developmental Biology 2026, 14: 1779094. PMID: 41929632, PMCID: PMC13038875, DOI: 10.3389/fcell.2026.1779094.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  Citations

• Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

  Drekolias D, Zahra F, Fileni C, Sallman D, Mo Q, Chan O, Zhang L, Vincelette N, Yu X, Sammut R, Moon J, Park J, Umasangtongkul S, Lledo F, Razabdouski T, Cheng C, Qin D, Mai K, Ball S, Shallis R, Xie Z, Kuykendall A, Padron E, Sweet K, Walker A, Komrokji R, Lancet J, Niyongere S, Cluzeau T, Yun S. Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents. Blood Cancer Discovery 2026, 7: 403-413. PMID: 41671569, PMCID: PMC12967238, DOI: 10.1158/2643-3230.bcd-25-0193.

  Peer-Reviewed Original Research

  Citations

  Altmetric

• Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.

  Boussi L, Bewersdorf J, Liu Y, Shallis R, Aguirre L, Bystrom R, Zucenka A, Garciaz S, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Berton G, Ling K, Zeidan A, Stein E, Shimony S, Goldberg A, Stahl M. Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities. Haematologica 2026 PMID: 41609030, DOI: 10.3324/haematol.2025.288891.

  Peer-Reviewed Original Research

  This study investigates the effectiveness of hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5/7 abnormalities, showing comparable remission rates but emphasizing stem cell transplant for long-term survival.

  Full Summary

• Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics

  Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Berton G, Stein E, Goldberg A, Mendez L, Zeidan A, Sallman D, Shimony S, Stahl M. Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics. Blood Neoplasia 2026, 3: 100201. PMID: 41859348, PMCID: PMC12997325, DOI: 10.1016/j.bneo.2026.100201.

  Peer-Reviewed Original Research

  Citations